Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DE1XF0
|
|||
| Drug Name |
DSG3-CAART
|
|||
| Drug Type |
CAR-T cell therapy
|
|||
| Indication | Pemphigus vulgaris [ICD-11: EB40; ICD-9: 694.4] | Phase 1 | [1] | |
| Company |
Cabaletta Bio Philadelphia, PA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Desmoglein-3 (DSG3) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04422912) A Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects With Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris. U.S.National Institutes of Health. | |||
| REF 2 | Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J Clin Invest. 2020 Dec 1;130(12):6317-6324. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.